Clinical Trials in Ballarat Central, Victoria

9 recruiting

Showing 19 of 9 trials

Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 2Phase 3

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled277 locationsNCT07063745
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled279 locationsNCT07221357
Recruiting
Phase 3

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Phase 3

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 2

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group90 enrolled11 locationsNCT05694936
Recruiting
Not Applicable

Indirect Calorimetry Guided Energy Provision in Critically Ill Patients With Obesity

ObesityCritical Illness
Australian and New Zealand Intensive Care Research Centre60 enrolled5 locationsNCT06053216